Lifestyle Asset Management Inc. Purchases 220 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Lifestyle Asset Management Inc. raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 3,917 shares of the company’s stock after acquiring an additional 220 shares during the quarter. Medpace accounts for 0.7% of Lifestyle Asset Management Inc.’s holdings, making the stock its 26th largest position. Lifestyle Asset Management Inc.’s holdings in Medpace were worth $1,301,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in MEDP. Iron Triangle Partners LP bought a new position in shares of Medpace during the 3rd quarter worth about $64,371,000. Clearbridge Investments LLC boosted its position in shares of Medpace by 55.1% during the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock valued at $166,343,000 after acquiring an additional 143,481 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Medpace by 62.3% during the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock valued at $127,941,000 after acquiring an additional 119,257 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after acquiring an additional 109,886 shares in the last quarter. Finally, DF Dent & Co. Inc. boosted its position in shares of Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock valued at $53,841,000 after acquiring an additional 105,659 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and decreased their target price for the company from $420.00 to $350.00 in a research report on Friday, September 27th. Robert W. Baird lifted their target price on shares of Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a research report on Monday, November 25th. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, Redburn Atlantic began coverage on shares of Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Medpace currently has an average rating of “Hold” and an average price target of $380.56.

Medpace Trading Up 0.8 %

Shares of MEDP stock opened at $347.90 on Friday. Medpace Holdings, Inc. has a 1 year low of $286.76 and a 1 year high of $459.77. The firm’s 50 day moving average is $339.40 and its 200-day moving average is $356.05. The firm has a market capitalization of $10.81 billion, a price-to-earnings ratio of 30.46, a PEG ratio of 1.77 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. During the same period in the prior year, the business earned $2.22 earnings per share. Medpace’s quarterly revenue was up 8.3% on a year-over-year basis. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.